scholarly journals Preserved Blood Pressure and Heart Rate Circadian Rhythm in Early Stage Alzheimer's Disease

1999 ◽  
Vol 54 (6) ◽  
pp. M304-M308 ◽  
Author(s):  
P. Cugini ◽  
M. C. Gori ◽  
C. M. Petrangeli ◽  
P. Tisei ◽  
F. Giubilei
2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
K. E. Innes ◽  
T. K. Selfe ◽  
C. J. Brown ◽  
K. M. Rose ◽  
A. Thompson-Heisterman

Objective. To investigate the effects of an 8-week meditation program on perceived stress, sleep, mood, and related outcomes in adults with cognitive impairment and their caregivers.Methods. Community-dwelling adults with a diagnosis of mild cognitive impairment or early-stage Alzheimer’s disease, together with their live-in caregivers, were enrolled in the study. After a brief training, participants were asked to meditate for 11 minutes, twice daily for 8 weeks. Major outcomes included measures of perceived stress (Perceived Stress Scale), sleep (General Sleep Disturbance Scale), mood (Profile of Mood States), memory functioning (Memory Functioning Questionnaire), and blood pressure. Participants were assessed pre- and post-intervention.Results. Ten participants (5 of 6 dyads) completed the study. Treatment effects did not vary by participant status; analyses were thus pooled across participants. Adherence was good (meditation sessions completed/week:X=11.4±1.1). Participants demonstrated improvement in all major outcomes, including perceived stress (P<0.001), mood (overall,P=0.07; depression,P=0.01), sleep (P<0.04), retrospective memory function (P=0.04), and blood pressure (systolic,P=0.004; diastolic,P=0.065).Conclusions. Findings of this exploratory trial suggest that an 8-week meditation program may offer an acceptable and effective intervention for reducing perceived stress and improving certain domains of sleep, mood, and memory in adults with cognitive impairment and their caregivers.


2015 ◽  
Vol 14 (3) ◽  
pp. 128 ◽  
Author(s):  
Joong-Seok Kim ◽  
Hyung-Eun Park ◽  
Yoon-Sang Oh ◽  
Jae-Young An ◽  
Sung-Kyung Park ◽  
...  

2020 ◽  
Vol 17 (1) ◽  
pp. 93-103 ◽  
Author(s):  
Jing Ma ◽  
Yuan Gao ◽  
Wei Tang ◽  
Wei Huang ◽  
Yong Tang

Background: Studies have suggested that cognitive impairment in Alzheimer’s disease (AD) is associated with dendritic spine loss, especially in the hippocampus. Fluoxetine (FLX) has been shown to improve cognition in the early stage of AD and to be associated with diminishing synapse degeneration in the hippocampus. However, little is known about whether FLX affects the pathogenesis of AD in the middle-tolate stage and whether its effects are correlated with the amelioration of hippocampal dendritic dysfunction. Previously, it has been observed that FLX improves the spatial learning ability of middleaged APP/PS1 mice. Objective: In the present study, we further characterized the impact of FLX on dendritic spines in the hippocampus of middle-aged APP/PS1 mice. Results: It has been found that the numbers of dendritic spines in dentate gyrus (DG), CA1 and CA2/3 of hippocampus were significantly increased by FLX. Meanwhile, FLX effectively attenuated hyperphosphorylation of tau at Ser396 and elevated protein levels of postsynaptic density 95 (PSD-95) and synapsin-1 (SYN-1) in the hippocampus. Conclusion: These results indicated that the enhanced learning ability observed in FLX-treated middle-aged APP/PS1 mice might be associated with remarkable mitigation of hippocampal dendritic spine pathology by FLX and suggested that FLX might be explored as a new strategy for therapy of AD in the middle-to-late stage.


Sign in / Sign up

Export Citation Format

Share Document